Non-viral CFTR gene delivery to the lungs of Cystic Fibrosis patients

Non-viral CFTR gene delivery to the lungs of Cystic Fibrosis patients

Detalhes bibliográficos
Autor principal:	Hyde, S
Formato:	Conference item
Publicado em:	2013

Registos relacionados

A randomized, double-blind, placebo-controlled trial of repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis
Por: Alton, E, et al.
Publicado em: (2015)

A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis
Por: Alton, EWFW, et al.
Publicado em: (2016)

Cystic fibrosis transmembrane conductance regulator (CFTR)-targeted therapeutics for cystic fibrosis
Por: Veselu, D-F, et al.
Publicado em: (2024)

Cystic Fibrosis and Oxidative Stress: The Role of CFTR
Por: Evelina Moliteo, et al.
Publicado em: (2022-08-01)

Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy.
Por: Davies, L, et al.
Publicado em: (2014)

Highly branched poly β-amino ester/CpG-depleted CFTR plasmid nanoparticles for non-viral gene therapy in lung cystic fibrosis disease
Por: Bei Qiu, et al.
Publicado em: (2024-09-01)

Inflammation and CFTR: Might Neutrophils be the Key in Cystic Fibrosis?
Por: V. Witko-Sarsat, et al.
Publicado em: (1999-01-01)

Challenges in the treatment of cystic fibrosis in the era of CFTR modulators
Por: Caroline Jacoby Schmidt, et al.
Publicado em: (2024-05-01)

Non-viral vectors in cystic fibrosis gene therapy: recent developments and future prospects.
Por: Pringle, I, et al.
Publicado em: (2009)

Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung.
Por: McLachlan, G, et al.
Publicado em: (2011)

Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial
Por: Alton, EWFW, et al.
Publicado em: (2015)

Therapeutic Approaches for Patients with Cystic Fibrosis Not Eligible for Current CFTR Modulators
Por: Isabelle Fajac, et al.
Publicado em: (2021-10-01)

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitylation as a Novel Pharmaceutical Target for Cystic Fibrosis
Por: Ryosuke Fukuda, et al.
Publicado em: (2020-04-01)

A new era of cystic fibrosis therapy with CFTR modulators
Por: Laura Gomes Boabaid de Barros, et al.
Publicado em: (2025-01-01)

Impact of CFTR modulators on exercise capacity in adolescents with cystic fibrosis
Por: Molla Imaduddin Ahmed, et al.
Publicado em: (2024-02-01)

SAFETY AND EXPRESSION OF A SINGLE DOSE OF LIPID-MEDIATED CFTR GENE THERAPY TO THE UPPER AND LOWER AIRWAYS OF PATIENTS WITH CYSTIC FIBROSIS
Por: Davies, G, et al.
Publicado em: (2011)

CFTR mutations spectrum and the efficiency of molecular diagnostics in Polish cystic fibrosis patients.
Por: Ewa Ziętkiewicz, et al.
Publicado em: (2014-01-01)

Medication adherence to CFTR modulators in patients with cystic fibrosis: a systematic review
Por: Carina M.E. Hansen, et al.
Publicado em: (2024-08-01)

CFTR pathogenic variants spectrum in a cohort of Mexican patients with cystic fibrosis
Por: Angélica Martínez-Hernández, et al.
Publicado em: (2024-04-01)

The Role of MMPs in the Era of CFTR Modulators: An Additional Target for Cystic Fibrosis Patients?
Por: Renata Esposito, et al.
Publicado em: (2023-02-01)

Eligibility of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator therapies: cohort of cystic fibrosis registry of Türkiye
Por: Meltem Akgül Erdal, et al.
Publicado em: (2025-02-01)

CFTR dysfunction leads to defective bacterial eradication on cystic fibrosis airways
Por: Min Wu, et al.
Publicado em: (2024-04-01)

CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
Por: Francesca Saluzzo, et al.
Publicado em: (2022-04-01)

CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
Por: Lucile Regard, et al.
Publicado em: (2022-05-01)

Capsaicin-Loaded Chitosan Nanocapsules for wtCFTR-mRNA Delivery to a Cystic Fibrosis Cell Line
Por: A. Katharina Kolonko, et al.
Publicado em: (2020-09-01)

A poly-functional gene delivery system for cystic fibrosis
Por: Montier, T, et al.
Publicado em: (2017)

Localization of the cystic fibrosis transmembrane conductance regulator (Cftr) to mouse chromosome 6.
Por: Siegel, D, et al.
Publicado em: (1992)

Diagnostic tools and CFTR functional assays in cystic fibrosis: utility and availability in Switzerland
Por: Clara Fernandez Elviro, et al.
Publicado em: (2021-04-01)

Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment
Por: Malinda Wu, et al.
Publicado em: (2024-06-01)

Cystic Fibrosis Bone Disease: The Interplay between CFTR Dysfunction and Chronic Inflammation
Por: Óscar Fonseca, et al.
Publicado em: (2023-02-01)

Emerging gene therapies for cystic fibrosis
Por: Miah, K, et al.
Publicado em: (2019)

Hypoglycaemia after Initiation of CFTR Modulator Therapy in a Cystic Fibrosis Patient without Diabetes
Por: Marie Yskout, et al.
Publicado em: (2023-01-01)

Differential thermostability and response to cystic fibrosis transmembrane conductance regulator (CFTR) potentiators of human and mouse F508del-CFTR
Por: Bose, S, et al.
Publicado em: (2019)

Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders
Por: Francesco Amati, et al.
Publicado em: (2024-06-01)

Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis
Por: Xiaoxuan Han, et al.
Publicado em: (2023-05-01)

Reporting three rare pathogenic variants at the CFTR gene in two unrelated Iranian Azeri children with cystic fibrosis
Por: S. Erfan Hosseini-Asl, et al.
Publicado em: (2024-10-01)

The effect of triple CFTR modulator therapy and azithromycin on ion channels and inflammation in cystic fibrosis
Por: Suhad Bani Melhim, et al.
Publicado em: (2024-12-01)

Editorial: Mechanisms of action of small molecules on CFTR mutants and the impact on cystic fibrosis pathogenesis
Por: Camille Ehre, et al.
Publicado em: (2024-06-01)

Optimizing CFTR modulator therapy management for cystic fibrosis through the ReX platform
Por: Karin Yaacoby-Bianu, et al.
Publicado em: (2023-12-01)

Cumulative CFTR expression following repeated aerosol delivery of non-viral pGM169/GL67A formulation to mouse lung
Por: Alton, E, et al.
Publicado em: (2012)